Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors.
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
25
11
2020
accepted:
11
02
2021
pubmed:
13
3
2021
medline:
13
3
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
To assess efficacy and safety of percutaneous cryoablation (CA) for advanced and refractory extra-abdominal desmoid tumors. This retrospective study reviewed 30 consecutive patients with symptomatic desmoid tumors evolving after "wait and watch" periods, and despite medical treatment, treated by CA between 2007 and 2019. Progression free survival (PFS), objective response rate, pain reduction (decreased of visual analogic scale pain (VAS)[Formula: see text] 3 or disappearance of pain), total volume lesion (TVL) and complications were documented. Kaplan Meier method was used to outline PFS. Paired sample t test was used to compare volume of tumors before treatment and at 1 and 3 year. With a median follow-up of 18.5 months (range 6-93 months, interquartile range (IQR): 12-55), the PFS was 85.1% at 1 year and 77.3% at 3 years. Objective response was obtained for 80% of patients with a complete response for 43% patients. Pain reduction was obtained for 96.7% (95% confidence interval (95% CI): 90.3, 100) of patients. Median volume of desmoid tumor before treatment was 124.1cm CA is an effective treatment for advanced and refractory extra-abdominal desmoid tumor, that induces durable responses.
Identifiants
pubmed: 33709291
doi: 10.1007/s10147-021-01887-y
pii: 10.1007/s10147-021-01887-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147-1158Références
Reitamo JJ, Häyry P, Nykyri E, Saxén E (1982) The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 77:665–673. https://doi.org/10.1093/ajcp/77.6.665
doi: 10.1093/ajcp/77.6.665
pubmed: 7091046
Nieuwenhuis MH, Casparie M, Mathus-Vliegen LMH et al (2011) A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer 129:256–261. https://doi.org/10.1002/ijc.25664
doi: 10.1002/ijc.25664
pubmed: 20830713
Fallen T, Wilson M, Morlan B, Lindor NM (2006) Desmoid tumors—a characterization of patients seen at Mayo Clinic 1976–1999. Fam Cancer 5:191–194. https://doi.org/10.1007/s10689-005-5959-5
doi: 10.1007/s10689-005-5959-5
pubmed: 16736290
Shields CJ, Winter DC, Kirwan WO, Redmond HP (2001) Desmoid tumours. Eur J Surg Oncol 27:701–706. https://doi.org/10.1053/ejso.2001.1169
doi: 10.1053/ejso.2001.1169
pubmed: 11735163
Bertario L, Russo A, Sala P et al (2001) Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 95:102–107. https://doi.org/10.1002/1097-0215(20010320)95:2%3c102::aid-ijc1018%3e3.0.co;2-8
doi: 10.1002/1097-0215(20010320)95:2<102::aid-ijc1018>3.0.co;2-8
pubmed: 11241320
Alman BA, Li C, Pajerski ME et al (1997) Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 151:329–334
pubmed: 9250146
pmcid: 1857985
Joglekar SB, Rose PS, Sim F et al (2011) Current perspectives on desmoid tumors: the Mayo clinic approach. Cancers 3:3143–3155. https://doi.org/10.3390/cancers3033143
doi: 10.3390/cancers3033143
pubmed: 24212949
pmcid: 3759190
Kasper B, Baumgarten C, Garcia J et al (2017) An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol Off J Eur Soc Med Oncol 28:2399–2408. https://doi.org/10.1093/annonc/mdx323
doi: 10.1093/annonc/mdx323
Briand S, Barbier O, Biau D et al (2014) Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am 96:631–638. https://doi.org/10.2106/JBJS.M.00988
doi: 10.2106/JBJS.M.00988
pubmed: 24740659
Toulmonde M, Pulido M, Ray-Coquard I et al (2019) Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 20:1263–1272. https://doi.org/10.1016/S1470-2045(19)30276-1
doi: 10.1016/S1470-2045(19)30276-1
pubmed: 31331699
Gounder MM, Mahoney MR, Van Tine BA et al (2018) Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 379:2417–2428. https://doi.org/10.1056/NEJMoa1805052
doi: 10.1056/NEJMoa1805052
pubmed: 30575484
pmcid: 6447029
Teshima M, Iwae S, Hirayama Y, Furukawa T (2012) Nonsteroidal anti-inflammatory drug treatment for desmoid tumor recurrence after surgery. Otolaryngol-Head Neck Surg 147:978–979. https://doi.org/10.1177/0194599812453561
doi: 10.1177/0194599812453561
pubmed: 22760417
Kono T, Tomita I, Chisato N et al (2004) Successful low-dose chemotherapy using vinblastine and methotrexate for the treatment of an ileoanal pouch mesenteric desmoid tumor: report of a case. Dis Colon Rectum 47:246–249. https://doi.org/10.1007/s10350-003-0025-6
doi: 10.1007/s10350-003-0025-6
pubmed: 15043298
Skapek SX, Anderson JR, Hill DA et al (2013) Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 60:1108–1112. https://doi.org/10.1002/pbc.24457
doi: 10.1002/pbc.24457
pubmed: 23281268
Magalov Z, Shitzer A, Degani D (2007) Isothermal volume contours generated in a freezing gel by embedded cryo-needles with applications to cryo-surgery. Cryobiology 55:127–137. https://doi.org/10.1016/j.cryobiol.2007.06.009
doi: 10.1016/j.cryobiol.2007.06.009
pubmed: 17719571
Gangi A, Tsoumakidou G, Buy X, Quoix E (2010) Quality improvement guidelines for bone tumour management. Cardiovasc Intervent Radiol 33:706–713. https://doi.org/10.1007/s00270-009-9738-9
doi: 10.1007/s00270-009-9738-9
pubmed: 20151138
pmcid: 2908451
Robinson D, Halperin N, Nevo Z (2001) Two freezing cycles ensure interface sterilization by cryosurgery during bone tumor resection. Cryobiology 43:4–10. https://doi.org/10.1006/cryo.2001.2312
doi: 10.1006/cryo.2001.2312
pubmed: 11812046
Kurup AN, Schmit GD, Morris JM et al (2017) Avoiding complications in bone and soft tissue ablation. Cardiovasc Intervent Radiol 40:166–176. https://doi.org/10.1007/s00270-016-1487-y
doi: 10.1007/s00270-016-1487-y
pubmed: 27826789
Kurup AN, Morris JM, Schmit GD et al (2013) Neuroanatomic considerations in percutaneous tumor ablation. Radiographics 33:1195–1215
doi: 10.1148/rg.334125141
Tsoumakidou G, Buy X, Garnon J et al (2011) Percutaneous thermal ablation: how to protect the surrounding organs. Tech Vasc Interv Radiol 14:170–176. https://doi.org/10.1053/j.tvir.2011.02.009
doi: 10.1053/j.tvir.2011.02.009
pubmed: 21767784
Tsoumakidou G, Garnon J, Ramamurthy N et al (2013) Interest of electrostimulation of peripheral motor nerves during percutaneous thermal ablation. Cardiovasc Intervent Radiol 36:1624–1628. https://doi.org/10.1007/s00270-013-0641-z
doi: 10.1007/s00270-013-0641-z
pubmed: 23665861
Kurtz J-E, Buy X, Deschamps F et al (2021) CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer 143:78–87. https://doi.org/10.1016/j.ejca.2020.10.035
doi: 10.1016/j.ejca.2020.10.035
pubmed: 33290994
U.S department of health and human services (2017) Common terminology criteria for adverse events (CTCAE), version 5.0
Redifer Tremblay K, Lea WB, Neilson JC et al (2019) Percutaneous cryoablation for the treatment of extra-abdominal desmoid tumors. J Surg Oncol 120:366–375. https://doi.org/10.1002/jso.25597
doi: 10.1002/jso.25597
pubmed: 31236956
pmcid: 6790665
Schmitz JJ, Schmit GD, Atwell TD et al (2016) Percutaneous cryoablation of extraabdominal desmoid tumors: a 10 year experience. Am J Roentgenol 207:190–195. https://doi.org/10.2214/AJR.15.14391
doi: 10.2214/AJR.15.14391
Havez M, Lippa N, Al-Ammari S et al (2014) Percutaneous image-guided cryoablation in inoperable extra-abdominal desmoid tumors: a study of tolerability and efficacy. Cardiovasc Intervent Radiol 37:1500–1506. https://doi.org/10.1007/s00270-013-0830-9
doi: 10.1007/s00270-013-0830-9
pubmed: 24402645
Bouhamama A, Lame F, Mastier C et al (2019) Local control and analgesic efficacy of percutaneous cryoablation for desmoid tumors. Cardiovasc Intervent Radiol. https://doi.org/10.1007/s00270-019-02323-5
doi: 10.1007/s00270-019-02323-5
pubmed: 31471720
Kujak JL, Liu PT, Johnson GB, Callstrom MR (2010) Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiol 39:175–182. https://doi.org/10.1007/s00256-009-0801-z
doi: 10.1007/s00256-009-0801-z
pubmed: 19768644
Alman B, Attia S, Baumgarten C et al (2020) The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 127:96–107. https://doi.org/10.1016/j.ejca.2019.11.013
doi: 10.1016/j.ejca.2019.11.013
Slovak R, Ludwig JM, Gettinger SN et al (2017) Immuno-thermal ablations–boosting the anticancer immune response. J Immunother Cancer 5:78. https://doi.org/10.1186/s40425-017-0284-8
doi: 10.1186/s40425-017-0284-8
pubmed: 29037259
pmcid: 5644150
Rozet I, Vavilala MS (2007) Risks and benefits of patient positioning during neurosurgical care. Anesthesiol Clin 25:631–653. https://doi.org/10.1016/j.anclin.2007.05.009
doi: 10.1016/j.anclin.2007.05.009
pubmed: 17884711
pmcid: 2265668
Eastley N, McCulloch T, Esler C et al (2016) Extra-abdominal desmoid fibromatosis: a review of management, current guidance and unanswered questions. Eur J Surg Oncol EJSO 42:1071–1083. https://doi.org/10.1016/j.ejso.2016.02.012
doi: 10.1016/j.ejso.2016.02.012
pubmed: 26965303